Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors ...

Taiho Pharmaceutical has agreed to acquire Swiss-based antibody-drug-conjugate (ADC) specialist Araris Biotech for up to $1.14bn, representing another big-dollar deal for the promising cancer ...

The acquisition follows a research collaboration between Taiho Pharmaceutical and Araris signed in November 2023 and is expected to be completed in the first half of 2025. Under the terms of the ...

In an untitled letter issued last Friday and made public this week, the FDA took aim at clinical data included on a doctor-facing web page for Taiho Oncology’s Lytgobi. Lytgobi is an FGFR ...

Japan's Taiho Pharma has reached a deal to buy Switzerland's Araris Biotech, around 18 months after they started collaborating on the development of antibody-drug conjugates (ADCs) for cancer.

Japan Year Ended March 31 GROUP 2025 2024 Revenue Y112.79 bln Y112.04 bln Operating Profit Y610.00 mln Y2.49 bln Pretax Profit Y910.00 mln Y3.24 bln Net Profit (Y4.19 bln) Y1.75 bln Per share Earnings ...

“We’re open for business,” said Taiho Oncology, Inc. CEO, Timothy Whitten. Alongside its growing pipeline of orally administered oncology drugs, the US subsidiary of Japan’s Taiho ...